Literature DB >> 11271379

Carnitine-acylcarnitine translocase deficiency: phenotype, residual enzyme activity and outcome.

E Lopriore1, R J Gemke, N M Verhoeven, C Jakobs, R J Wanders, A B Roeleveld-Versteeg, B T Poll-The.   

Abstract

UNLABELLED: Carnitine-acylcarnitine translocase deficiency is a rare and life-threatening mitochondrial fatty acid beta-oxidation disorder. We describe a patient who, despite a severe clinical course and an extremely low carnitine-acylcarnitine translocase activity, is currently alive and in good health. We performed an extensive analysis of all previously published cases in order to evaluate the clinical features and prognostic factors. Reports on 21 patients with carnitine-acylcarnitine translocase deficiency were obtained. Only 5 out of the 21 patients survived early childhood. At least 20 siblings are reported to have died of sudden unexplained death in the neonatal period. Although phenotype and residual enzyme activity have been suggested to be related to outcome, we were not able to establish such a relationship.
CONCLUSION: Phenotype and residual enzyme activity do not appear to be major prognostic factors. Vigorous work-up in order to reach an expedite diagnosis and prompt medical intervention during acute episodes, especially in the neonatal period, may prevent fatal complications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11271379     DOI: 10.1007/s004310000644

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  7 in total

Review 1.  Fatty acid oxidation disorders.

Authors:  J Lawrence Merritt; Marie Norris; Shibani Kanungo
Journal:  Ann Transl Med       Date:  2018-12

2.  Carnitine-acylcarnitine translocase deficiency: experience with four cases in Spain and review of the literature.

Authors:  Isidro Vitoria; Elena Martín-Hernández; Luis Peña-Quintana; María Bueno; Pilar Quijada-Fraile; Jaime Dalmau; Sofia Molina-Marrero; Belén Pérez; Begoña Merinero
Journal:  JIMD Rep       Date:  2015-01-23

3.  L-carnitine in inborn errors of metabolism: what is the evidence?

Authors:  J H Walter
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 4.  Evaluation of the child with suspected mitochondrial liver disease.

Authors:  Jean P Molleston; Ronald J Sokol; Wikrom Karnsakul; Alexander Miethke; Simon Horslen; John C Magee; René Romero; Robert H Squires; Johan L K Van Hove
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-09       Impact factor: 2.839

5.  Transcriptional Regulation of the Mitochondrial Citrate and Carnitine/Acylcarnitine Transporters: Two Genes Involved in Fatty Acid Biosynthesis and β-oxidation.

Authors:  Vito Iacobazzi; Vittoria Infantino; Ferdinando Palmieri
Journal:  Biology (Basel)       Date:  2013-01-29

Review 6.  Carnitine Inborn Errors of Metabolism.

Authors:  Mohammed Almannai; Majid Alfadhel; Ayman W El-Hattab
Journal:  Molecules       Date:  2019-09-06       Impact factor: 4.411

7.  Late-Onset Carnitine-Acylcarnitine Translocase Deficiency With SLC25A20 c.199-10T>G Variation: Case Report and Pathologic Analysis of Liver Biopsy.

Authors:  Min Chen; Yao Cai; Sitao Li; Hui Xiong; Mengxian Liu; Fei Ma; Xin Xiao; Hu Hao
Journal:  Front Pediatr       Date:  2020-10-30       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.